BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 11720279)

  • 21. Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
    Björk T; Schalken J; Wittjes W; Ljungberg B; Lilja H
    Prostate; 2001 Apr; 47(1):14-20. PubMed ID: 11304725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer.
    Pannek J; Rittenhouse HG; Evans CL; Finlay JA; Bruzek DJ; Cox JL; Chan DW; Subong EN; Partin AW
    Urology; 1997 Nov; 50(5):715-21. PubMed ID: 9372881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
    Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.
    Haese A; Becker C; Noldus J; Graefen M; Huland E; Huland H; Lilja H
    J Urol; 2000 May; 163(5):1491-7. PubMed ID: 10751864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
    Becker C; Piironen T; Pettersson K; Hugosson J; Lilja H
    Urology; 2000 May; 55(5):694-9. PubMed ID: 10792083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
    Becker C; Piironen T; Pettersson K; Hugosson J; Lilja H
    J Urol; 2003 Oct; 170(4 Pt 1):1169-74. PubMed ID: 14501718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.
    Haese A; Graefen M; Becker C; Noldus J; Katz J; Cagiannos I; Kattan M; Scardino PT; Huland E; Huland H; Lilja H
    Prostate; 2003 Feb; 54(3):181-6. PubMed ID: 12518322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.
    Shariat SF; Gottenger E; Nguyen C; Song W; Kattan MW; Andenoro J; Wheeler TM; Spencer DM; Slawin KM
    Cancer Res; 2002 Oct; 62(20):5974-9. PubMed ID: 12384565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels.
    Charlesworth MC; Young CY; Klee GG; Saedi MS; Mikolajczyk SD; Finlay JA; Tindall DJ
    Urology; 1997 Mar; 49(3):487-93. PubMed ID: 9123724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
    Stephan C; Jung K; Nakamura T; Yousef GM; Kristiansen G; Diamandis EP
    Int J Urol; 2006 Mar; 13(3):238-43. PubMed ID: 16643616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
    Steuber T; Vickers AJ; Serio AM; Vaisanen V; Haese A; Pettersson K; Eastham JA; Scardino PT; Huland H; Lilja H
    Clin Chem; 2007 Feb; 53(2):233-40. PubMed ID: 17185368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker.
    Darson MF; Pacelli A; Roche P; Rittenhouse HG; Wolfert RL; Young CY; Klee GG; Tindall DJ; Bostwick DG
    Urology; 1997 Jun; 49(6):857-62. PubMed ID: 9187691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis.
    Partin AW; Catalona WJ; Finlay JA; Darte C; Tindall DJ; Young CY; Klee GG; Chan DW; Rittenhouse HG; Wolfert RL; Woodrum DL
    Urology; 1999 Nov; 54(5):839-45. PubMed ID: 10565744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PSA and other tissue kallikreins for prostate cancer detection.
    Stephan C; Jung K; Lein M; Diamandis EP
    Eur J Cancer; 2007 Sep; 43(13):1918-26. PubMed ID: 17689069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Molecular forms of prostate-specific antigen and human kallikrein 2 as possible indicators in prostatic carcinoma diagnosis].
    Lein M; Stephan C; Jung K; Schnorr D; Loening SA
    Urologe A; 2000 Jul; 39(4):313-23. PubMed ID: 10957772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer.
    Karazanashvili G; Abrahamsson PA
    J Urol; 2003 Feb; 169(2):445-57. PubMed ID: 12544286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.
    Steuber T; Vickers A; Haese A; Kattan MW; Eastham JA; Scardino PT; Huland H; Lilja H
    Int J Cancer; 2007 Apr; 120(7):1499-504. PubMed ID: 17205511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early prediction of prostate cancer biochemical recurrence and identification of disease persistence using PSA isoforms and human kallikrein-2.
    Do Carmo Silva J; Vesely S; Luksanova H; Prusa R; Babjuk M
    Tumour Biol; 2021; 43(1):197-207. PubMed ID: 34486998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical significance of expression of PSA, hK2, PSMA in the peripheral blood of patients with prostate cancer].
    Cui WG; Zhao H; Song YZ; Zhang J; Zhang LG; Shi JD; Qiang WM
    Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):479-81. PubMed ID: 15555338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of hK2, free PSA, and complexed PSA measurements in the very early detection of prostate cancer.
    Lilja H
    Eur Urol; 2001 Apr; 39 Suppl 4():47-8. PubMed ID: 11340291
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.